Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients (J Gastroenterol, 10.1007/s00535-016-1274-1);Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

Journal of Gastroenterology

Volumn 52, Issue 7, 2017, Pages 788-799

  Iborra, Marisa ^a   Pérez Gisbert, Javier ^b   Bosca Watts, Marta Maia ^c   López García, Alicia ^d   García Sánchez, Valle ^e   López Sanromán, Antonio ^f   Hinojosa, Esther ^g   Márquez, Lucía ^h   García López, Santiago ⁱ   Chaparro, María ^j   Aceituno, Montserrat ^k   Calafat, Margalida ^l   Guardiola, Jordi ^k   Belloc, Blanca ^m   Ber, Yolanda ⁿ   Bujanda, Luis ^o   Beltrán, Belén ^a   Rodríguez Gutiérrez, Cristina ^p   Barrio, Jesús ^q   Cabriada, José Luis ^r   Rivero, Montserrat ^s   Camargo, Raquel ^t   van Domselaar, Manuel ^u   Villoria, Albert ^v   Schuterman, Hugo Salata ^w   Hervás, David ^x   Nos, Pilar ^a   more..

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF CÓRDOBA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL DE MANISES   (Spain)

^h Servei de Digestiu Consorci Hospitalari de Vic   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^j Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^m HOSPITAL SAN JORGE   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^o UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^p Universidad Pública de Navarra   (Spain)

^q HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^r HOSPITAL DE GALDAKAO   (Spain)

^s HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^t HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^u HOSPITAL UNIVERSITARIO DE TORREJÓN   (Spain)

^v INSTITUTO DE SALUD CARLOS III   (Spain)

^w HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^x INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

more..

Author keywords

Adalimumab; Treatment; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; CYCLOSPORINE; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ABSCESS; ADULT; ARTICLE; BRONCHITIS; CLINICAL PRACTICE; COHORT ANALYSIS; COLON RESECTION; COLONOSCOPY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FECES LEVEL; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; REMISSION; SINUSITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; FECES; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; RETREATMENT; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; COLECTOMY; COLITIS, ULCERATIVE; DISEASE PROGRESSION; FECES; FEMALE; HOSPITALIZATION; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REMISSION INDUCTION; RETREATMENT; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84990938430     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-016-1293-y     Document Type: Erratum

References (34)

1. Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver. 2015;9:18–27.
2. Seo GS, Chae SC. Biological therapy for ulcerative colitis: an update. World J Gastroenterol. 2014;20:13234–8.
3. Tursi A, Penna A. Onset of ulcerative colitis under treatment with adalimumab. Am J Gastroenterol. 2008;103:2410–2.
4. Barreiro-de Acosta M, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol. 2009;15:3814–6.
5. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007;13:2328–32.
6. Taxonera C, Estelles J, Fernandez-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33:340–8.
7. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15:1302–7.
8. Gies N, Kroeker KI, Wong K, et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther. 2010;32:522–8.
9. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–7.
10. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–65.
11. Armuzzi A, Biancone L, Daperno M, et al. Adalimumab in active ulcerative colitis: a ‘‘real-life’’ observational study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:738–43.
12. McDermott E, Murphy S, Keegan D, et al. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohn’s Colitis. 2013;7:150–3.
13. Garcia-Bosch O, Gisbert JP, Canas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohn’s Colitis. 2013;7:717–22.
14. Danese S. Adalimumab in ulcerative colitis: ready for prime time. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:8–13.
15. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohn’s Colitis. 2012;6:965–90.
16. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology = Journal canadien de gastroenterologie. 2005;19(Suppl A):5A–36A.
17. Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613–23.
18. Armstrong BG, Sloan M. Ordinal regression models for epidemiologic data. Am J Epidemiol. 1989;129:191–204.
19. Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283–94.
20. Ma C, Panaccione R, Heitman SJ, et al. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther. 2009;30:977–86.
21. Guardiola J, Lobaton T, Rodriguez-Alonso L, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014;12:1865–70.
22. Christensen KR, Steenholdt C, Brynskov J. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study. Scand J Gastroenterol. 2015;50:1018–24.
23. Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.
24. Busquets D, Aldeguer X. Clinical experience with adalimumab in anti-TNF-naive patients with ulcerative colitis. J Crohn’s Colitis. 2013;7:e195.
25. Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD—the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013;38:1188–97.
26. Ma C, Huang V, Fedorak DK, et al. Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response. J Clin Gastroenterol. 2015;49:675–82.
27. Reinisch W. How to manage loss of response to anti-TNF in Crohn’s disease? Curr Drug Targets. 2010;11:152–5.
28. Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo. 2009;61:107–17.
29. Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology. 2015;149(1275–1285):e1272.
30. Soubieres AA, Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7:41–50.
31. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008;28:966–72.
32. Balint A, Farkas K, Palatka K, et al. Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. J Crohn’s Colitis. 2016;10:26–30.
33. Hussey M, Mc Garrigle R, Kennedy U, et al. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2016;28:217–21.
34. Tursi A, Elisei W, Picchio M, et al. Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first ‘‘real-life’’ experience in primary gastroenterology centers in Italy. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2014;27:369–73.